<DOC>
	<DOCNO>NCT00561301</DOCNO>
	<brief_summary>- To evaluate feasibility combination chemotherapy comprise gemcitabine-dexamethasone-oxaliplatin patient refractory relapse malignant non-Hodgkin lymphoma ( NHL )</brief_summary>
	<brief_title>Biweekly Gemcitabine-Oxaliplatin Dexamethasone Relapsed/Refractory Malignant Lymphoma</brief_title>
	<detailed_description>- The feasibility evaluate term objective response rate , efficacy stem cell collection , disease-free survival , overall survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>Patients refractory firstline CHOPlike regimen Patients first relapse firstline CHOPlike regimen upfront autologous allogeneic hematopoietic stem cell transplantation Age 15 year ECOG performance status â‰¤ 2 Adequate bone marrow function Adequate kidney , liver , cardiac Patients receive GEM OX</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>